Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001104659-25-011486
Filing Date
2025-02-11
Accepted
2025-02-11 16:15:14
Documents
1
Period of Report
2025-02-09

Document Format Files

Seq Description Document Type Size
1 OWNERSHIP DOCUMENT tm256086-1_4seq1.html 4  
1 OWNERSHIP DOCUMENT tm256086-1_4seq1.xml 4 6992
  Complete submission text file 0001104659-25-011486.txt   8637
Mailing Address GLENPOINTE CENTRE EAST, 3RD FLOOR 300 FRANK W. BURR BLVD., SUITE 21 TEANECK NJ 07666
Business Address GLENPOINTE CENTRE EAST, 3RD FLOOR 300 FRANK W. BURR BLVD., SUITE 21 TEANECK NJ 07666 201-329-7300
PHIBRO ANIMAL HEALTH CORP (Issuer) CIK: 0001069899 (see all company filings)

EIN.: 131840497 | State of Incorp.: DE | Fiscal Year End: 0630
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address C/O ZOETIS INC. 10 SYLVAN WAY PARSIPPANY NJ 07054
Business Address
David Glenn (Reporting) CIK: 0001606256 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-36410 | Film No.: 25610000